腫瘤過繼免疫療法之DC-CIK課件_第1頁
腫瘤過繼免疫療法之DC-CIK課件_第2頁
腫瘤過繼免疫療法之DC-CIK課件_第3頁
腫瘤過繼免疫療法之DC-CIK課件_第4頁
腫瘤過繼免疫療法之DC-CIK課件_第5頁
已閱讀5頁，還剩25頁未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

5

腫瘤過繼免疫療法之DC-CIK4

腫瘤過繼免疫療法之DC-CIK3

腫瘤過繼免疫療法之DC-CIK2

腫瘤過繼免疫療法之DC-CIK1

腫瘤過繼免疫療法之DC-CIKDC-CIKadoptiveimmunotherapyPresentedby

ShenJingyi，WangKun，DuXu，ZhangZhaopeng，WangYue，RenShanwu腫瘤過繼免疫療法之DC-CIKThefourthtreatmentmodeofcancerActiveimmunotherapyTargetimmunotherapyAdoptiveimmunotherapy:DC-CIK

BiotherapeuticsCytokinetherapyGenetherapy腫瘤過繼免疫療法之DC-CIKDC-CIKDC-CIK·Oneofthehottestsubjectinbiotherapyoftumor·CIKdiscoveredbySchmidtWolf（StanfordUniversity）1991腫瘤過繼免疫療法之DC-CIKPrinciplesPrinciplesDCandCIKthatobtainedfromperipheralbloodandinducedbydifferentcytokinesinvitro,cankilltumorcellsspeciallyinvivowhentransfusedbacktotumorpatients.腫瘤過繼免疫療法之DC-CIKDendriticCellsDistribution:alltissuesofourbodyexceptbrainandtestisThemostpowerfulprofessionalAPCthatcanactivatenaiveTcellInitiatorofspecficCMIWhatisDCs腫瘤過繼免疫療法之DC-CIK腫瘤過繼免疫療法之DC-CIKRoleofDCinDC-CIKtherapyInducingAg-specificCTLresponse1IncreasingtheproliferationofCIK2EnhancingcytotixcityofCIK3RoleofDCinDC-CIKtherapyInhibitingCD4+CD25+

Treg4腫瘤過繼免疫療法之DC-CIKCIK:Cytokine-inducedKillerDefinition1Characteristics2Mainmachanisms3Comparationswithotherimmunotherapeuticcells4腫瘤過繼免疫療法之DC-CIKDefinitionofCIKCIKisheterogeniccytotoxicTlymphocyteinducedbymanycytokinessuchasIL-2、IFN-γandanti-CD3Abinvitro,includingCD3+CD56+、CD3+CD8+Tlymphocytes腫瘤過繼免疫療法之DC-CIKCharacteristicsofCIKStrongabilityofproliferationHighefficiencyinkillingdifferenttumorcellsNon-MHCrestrictionWideanti-tumorspectrum腫瘤過繼免疫療法之DC-CIKMachanismsofkillingtumors

Directway:Adhesionandreleaseofgranzyme

SecrationofCK:

IFN-γ

、IL-2、IL-6、

TNF-α﹠GM-CSF

Inductionapoptosis﹠necrosisoftumorcells腫瘤過繼免疫療法之DC-CIK腫瘤過繼免疫療法之DC-CIKDC:Recognizing﹠presentingtumorantigenCIK:Killingtumorcellsefficiently↓CocultureofDCwithCIK→AnincreaseofcytotoxicityaganisttumorcellsCoperationofdifferentimmunocytesandpowerfulimmunityfunction腫瘤過繼免疫療法之DC-CIKComparationswithotherimmunotherapeuticcellsSimilarity:ImmunotherapeuticcellsinducedbycytokinesfromPBMNCDifferences:CIK:MoreefficientWiderrangeofanti-tumorspectumNon-MHCrestriction腫瘤過繼免疫療法之DC-CIKSoursesofCIKPeripheralblood:Frompatienthimself:Nocross-infectionFromallogeneicdonors:WidesoursesUmbilicalcordblood:NosevereHVARBonemarrow

腫瘤過繼免疫療法之DC-CIKStepsStepsCollectiongofperipheralblood→Centrifuge﹠Resuspension→CultureinAIM-Vmedium→AdddifferentcytokinesforinducedpreliferationofDC﹠CIK→AddtumorcelllysesinDCsolution→CocultureofDC﹠CIK→Autologoustransfusion腫瘤過繼免疫療法之DC-CIKSteps腫瘤過繼免疫療法之DC-CIKInductionbyCIKinvitroAnti-CD3Ab:StimulateCIK

proliferationINF-γ、IL-2:EnhancingcytotoxicityofCIKDifferentaddingsequence,

differentresults腫瘤過繼免疫療法之DC-CIKEvaluationoftherapeuticeffectMorphologicaltest:SizechangeoftumorTumormarkertest:AFPCEACAI199Immunologicaldetection:TlymphocytessubgroupetcOverallresponserate:CR+PR+MRLifequalityevalationSurvivaltimeobservation腫瘤過繼免疫療法之DC-CIKApplicationScopeofDC-CIKAftersurgicaloperation,

chemotherapy﹠radiotherapyThetumorpatientswhocannotsustainthesideeffectsofradiotherapyandchemotherapyanylonger腫瘤過繼免疫療法之DC-CIKAdvantagesofDC-CIKComparedwithtriditionaltherapies:NoharmtoimmunitysystemWiderspectumoftumortherapySpecificrecognitionandkillingoftumorcells腫瘤過繼免疫療法之DC-CIKSideEffectofDC-CIKAdversereaction:RareandmildMostcommonreaction:Fever(spontaneousremission)Mainreason:IL-2(endo

溫馨提示

  • 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論